Evidence map›Paper›PMID 36005738›Full record

ReviewCell cycle (Georgetown, Tex.)2023

Cell cycle control by the insulin-like growth factor signal: at the crossroad between cell growth and mitotic regulation.

Pierluigi Scalia, Stephen J Williams, Yoko Fujita-Yamaguchi, Antonio Giordano

Open access · bronzeAbstract readReview
In one paragraph

Review in Cell cycle (Georgetown, Tex.), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 9 papers.

0numbers the graph read from it
0cells of the map it votes in
9citing papers in PubMed
1.3field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

9 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Insulin-like growth factor 1 receptor (Frontiers in cell and developmental biology · 2026
    Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Review
  9. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 4 institutions in 2 countries.

Pierluigi ScaliaISOPROG-Somatolink EPFP Research Network, Philadelphia, PA, USA, Caltanissetta, Italy.
Stephen J WilliamsISOPROG-Somatolink EPFP Research Network, Philadelphia, PA, USA, Caltanissetta, Italy.
Yoko Fujita-YamaguchiArthur Riggs Diabetes & Metabolism Research Institute, Beckman Research Institute of City of Hope, Duarte, CA, USA.
Antonio GiordanoISOPROG-Somatolink EPFP Research Network, Philadelphia, PA, USA, Caltanissetta, Italy.
City of Hope · USResearch Network (United States) · USTemple University · USUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

In proliferating cells and tissues a number of checkpoints (G1/S and G2/M) preceding cell division (M-phase) require the signal provided by growth factors present in serum. IGFs (I and II) have been demonstrated to constitute key intrinsic components of the peptidic active fraction of mammalian serum. In vivo genetic ablation studies have shown that the cellular signal triggered by the IGFs through their cellular receptors represents a non-replaceable requirement for cell growth and cell cycle progression. Retroactive and current evaluation of published literature sheds light on the intracellular circuitry activated by these factors providing us with a better picture of the pleiotropic mechanistic actions by which IGFs regulate both cell size and mitogenesis under developmental growth as well as in malignant proliferation. The present work aims to summarize the cumulative knowledge learned from the IGF ligands/receptors and their intracellular signaling transducers towards control of cell size and cell-cycle with particular focus to their actionable circuits in human cancer. Furthermore, we bring novel perspectives on key functional discriminants of the IGF growth-mitogenic pathway allowing re-evaluation on some of its signal components based upon established evidences.

Indexed as

Cell Cycle CheckpointsInsulin-Like Growth Factor IReceptor, InsulinSomatomedinsAnimalsCell CycleCell ProliferationHumansMammalsReceptor, IGF Type 1Receptors, SomatomedinInsulin-Like Growth Factor IReceptor, IGF Type 1Receptor, InsulinReceptors, SomatomedinSomatomedinsGFGHgrowth factorgrowth hormoneHybRHybR-Aigf1/2igf1rIGF1RIGF1R/IR-AIGF1R/IR hybrid receptorigf2r/m6pr/SpI2-6IGF-I/II: insulin like growth factor peptidesIGF-Type I receptor geneinsrinsulin like growth factor genesInsulin-like growth factor receptorinsulin receptor geneinsulin receptor proteininsulin receptor substrateIR-AIR (also InsR)IR isoform A (exon 11-)IRSmammalian target of rapamycinmTORmTORCmTOR complex. additional acronyms are clarified in the textproperty of a GF to increase growth (hypertrophy) and number (hyperplasia) of a target cell or tissuereceptor tyrosine kinaseRTK(scavenger protein for IGF2 & mannose-6-phosphate)trans-membrane high affinity IGF2 scavenger proteintrophic (effect)type I (protein)

Identifiers

PMID36005738
PMCPMC9769454
OpenAlexW4293104776

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.